TORONTO--(BUSINESS WIRE)-- Renzo DiCarlo, CEO of BioPharma Services Inc.. was proud to be invited to appear as a witness before the House of Commons’ Standing Committee on International Trade, in view of its study entitled Canada’s International Trade and Investment Policy: Selected Considerations Concerning COVID-19 Vaccines.

As a London School of Economics (LSE) alumnus in stakeholder theory research with 25 years of experience in Pharmaceutical GMP and Medical research, Renzo DiCarlo is uniquely qualified to comment on Canada’s future strategy to manage COVID-19, vaccination cycles and the Variants of Concern (VOC) that are now appearing.

The Standing Committee is commissioned to undertake a study of Canada’s trade and investment policy, and trade agreements in respect of how they may help or hinder the production and distribution of COVID-19 vaccines in Canada and across the world.

Throughout the pandemic, BioPharma Services Inc. has continued to offer leading edge research and development services to its global partners. Renzo DiCarlo remarked, “I am proud to be able to offer a clinical research perspective and represent BioPharma Services’ innovative work before the Committee. The vaccine and trade issues being addressed by this study will have far reaching impact, not just for the research industry, but for our nation as we work to overcome the challenges of COVID-19.”

Watch Renzo DiCarlo present his position on trading blocs, COVID-19 vaccinations and using breakthrough technologies to battle the new Variants of Concern and more.

About BioPharma Services Inc.

BioPharma Services Inc. is a full-service Contract Research Organization (CRO) specializing in the conduct of Phase I/IIa and Bioequivalence clinical trials for international pharmaceutical companies worldwide. BioPharma has clinical facilities both in the USA and Canada with a total capacity of 300 beds with access to healthy volunteers and special populations. Headquartered in Toronto, Canada, BioPharma’s comprehensive services also include Bioanalysis at our GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Data Management and Medical Writing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005938/en/